Dhanuka Agritech Limited has informed the Exchange regarding Outcome of Board Meeting held on May 16, 2025.
DHANUKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with a clean (unmodified) opinion from statutory auditors S S Kothari Mehta & Co LLP. Revenue from operations grew about 15.7% YoY to Rs. 2,03,515 lacs, while consolidated profit after tax rose roughly 24% to Rs. 29,696 lacs, reflecting margin expansion. The Board recommended a final dividend of Rs. 2 per share (100% on Rs. 2 face value), with record date July 18, 2025, to be paid within 30 days of the 40th AGM on August 1, 2025. During the year, the company completed a Rs. 100 crore buyback (5 lakh shares at Rs. 2,000 each) and acquired international rights for active ingredients Iprovalicarb and Triadimenol from Bayer AG, targeting expansion into 20+ countries. Independent Director Mr. Siraz Azmat Chaudhary will cease to be a director after completing his first term on July 22, 2025.
A solid topline and stronger profit growth signal healthy demand and improving margins for this agro-chemical player. The clean audit, 100% dividend, completed buyback, and international expansion push are shareholder-friendly and likely to be viewed positively by the market.